Clinical Trial Update: A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the immunogenicity and safety of a recombinant respiratory syncytial virus vaccine in adults aged 60 and older; the trial is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Recombinant RSV vaccine (RSV vaccine, recombinant)

Snippet

Sponsor: Guangzhou Patronus Biotech Co., Ltd. | Conditions: Respiratory Syncytial Virus Infection Prevention | Phase 2 | Status: ACTIVE_NOT_RECRUITING